FDA's New Center for Tobacco Products (CTP)
July 20, 2010
The United States Food and Drug Administration (FDA) is committed to maintaining open communications internationally to help ensure that our foreign partners are aware of FDA programs and initiatives that have global impact. Through our Office of International Programs, FDA works in a variety of ways to enhance international cooperation, including establishing 11 foreign posts in China, Europe, India and Latin America with plans for posts in the Middle East. Part of our public health mission is to build relationships with our foreign counterparts through information exchanges such as regular Embassy briefings.
As you may be aware, approximately one year ago, United States President Barack Obama signed legislation that gave the FDA regulatory oversight of tobacco products for the first time to FDA. We have been extremely busy over the past year implementing that legislation and establishing our new Center for Tobacco Products. I know there have been many questions in the international community about this new legislation and about FDA's role in the regulation of tobacco products in the United States. Therefore, I would like to cordially invite you and/or senior representatives from your Embassy to a briefing on this topic featuring the FDA's new Center for Tobacco Products (CTP).
Dr. Lawrence Deyton, CTP's Director, and key members of his staff will provide an overview of the Center, the legislation that President Barack Obama signed one year ago, and FDA's efforts to implement that legislation one year on. A draft agenda for this Embassy briefing is enclosed. For information about the new legislation, please visit our website at:
The Embassy briefing will be held on Wednesday, September 15, 2010, from 1:00 p.m to 4:00 p.m. (EDT) in the Ambassador Room at the Hilton Embassy Row Hotel, located at 2015 Massachusetts Avenue, N.W., in Washington, D.C.
We hope you and/or your staff will be able join us for what we believe will be a very interesting and informative briefing by Dr. Deyton. We would ask that you please take a few minutes to complete the online registration form for this Embassy briefing by September 1st (the form can be found at: www.blsmeetings.net/USFDAOIP-CTPEmbassyBriefing201O (Registration is closed)
For questions about the briefing, please contact Ms. Vashti Klein, Assistant Director for International Communications for our Office of International Programs. She can be reached at 301-796-8375, or by email at: OIPCommunications@fda.hhs.gov.
I look forward to welcoming you and your staff on September 15. Until then, please accept my warmest personal regards.
Murray M. Lumpkin, M.D., M.Sc.